News & Presentations

UPCOMING EVENTS

Date	Title	Documents
June 8, 2022	Corporate Presentation - June 8, 2022	Add Files Corporate Presentation - June 8, 2022 8 MB
October 21, 2021	OIS Glaucoma Innovation Summit	Add Files OIS Glaucoma Innovation Summit 797.7 KB
October 7, 2021	OIS Retina Innovation Showcase	Add Files OIS Retina Innovation Showcase 1.1 MB

Date	Title and Summary	Additional Formats
Toggle SummaryOctober 22, 2009	Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue	View HTML Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study 22 KB
Toggle SummaryOctober 26, 2009	Biocentury - RhoKing Glaucoma	View HTML
Toggle SummaryMarch 7, 2011	Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio Financing Underscores Strong Clinical Progress and Positive Data in Lead Program	View HTML Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio 24 KB
Toggle SummaryApril 12, 2011	American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension	View HTML